D Zibrak, Joseph
Price, David
Article History
Received: 1 October 2013
Revised: 2 July 2014
Accepted: 8 July 2014
First Online: 11 September 2014
Competing interests
: JDZ is a member of the InterMune Pharmaceuticals Clinical Advisory Board. DP has been a consultant to and/or member of the advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Medapharma, Merck, Mundipharma, Napp, Novartis, Nycomed, Pfizer, Sandoz and Teva. He or his research team have received grants and support for research in respiratory disease from the following organisations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Orion, Pfizer, Takeda and Teva. He has received payment for lectures from Activaero, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Napp, Novartis, Pfizer and Teva, and has been paid for development of educational materials by Boehringer Ingelheim and GlaxoSmithKline. He has been reimbursed for travel expenses by Boehringer Ingelheim, Merck, Mundipharma Napp, Novartis and Teva. He holds shares in AKL, which produces phytopharmaceuticals and owns 80% of Research in Real Life and its subsidiary social enterprise Optimum Patient Care.